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ABSTRACT 
Background: In pregnancy early interventions are recommended for prevention of mother-
to-child-transmission (PMTCT) of HIV. We examined whether pregnant women who live with 
HIV in Europe and are migrants encounter barriers in accessing HIV testing and care. 
Methods: Four cohorts within the European Pregnancy and Paediatric HIV Cohort 
Collaboration (EPPICC) provided data for pooled analysis of 11795 pregnant women who 
delivered in 2002-2012 across ten European countries. We defined a migrant as a woman 
delivering in a country different from her country of birth and grouped the countries into 
seven world regions. We compared three suboptimal PMTCT interventions (HIV diagnosis in 
late pregnancy in women undiagnosed at conception, late ART start in women diagnosed 
but untreated at conception and detectable viral load at delivery in women on antenatal ART) 
in native and migrant women using multivariable logistic regression models.  
Results:  Data included 9421 (79.9%) migrant women, mainly from sub-Saharan Africa 
(SSA); 4134 migrant women were diagnosed in the current pregnancy, often (48.6%) 
presenting with CD4 count<350 cells/µL. Being a migrant was associated with HIV diagnosis 
in late pregnancy (OR for SSA vs native women, 2.12[95%CI 1.67, 2.69]) but not with late 
ART start if diagnosed but not on ART at conception, or with detectable viral load at delivery 
once on ART. 
Conclusion: Migrant women were more likely to be diagnosed in late pregnancy but once 
on ART virological response was good. Good access to antenatal care enables the 
implementation of PMTCT protocols and optimises both maternal and children health 
outcomes generally. 
Key words: HIV, pregnancy, migrant, prevention of mother-to-child-transmission, antenatal 
care, women
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INTRODUCTION 
In pregnant women with HIV, antenatal anti-retroviral therapy (ART) is crucial for viral 
suppression during pregnancy and at delivery and the prevention of mother-to-child-
transmission (PMTCT).1 It is recommended that women conceiving on ART should continue 
ART during pregnancy and that those untreated at conception – i.e. women who are newly 
HIV-diagnosed in pregnancy and those already HIV-diagnosed but not treated – should start 
ART in early pregnancy.2 To ensure prompt antenatal ART start in women who are 
undiagnosed at conception it is recommended that HIV screening should be performed in 
early pregnancy. 
Migrant populations living in Europe are disproportionally affected by HIV3 but may face 
barriers in accessing HIV testing and care,4-6 including pregnant women. Migrant women 
may be less likely to receive optimum antenatal care than native women,7, 8 potentially 
leading to delayed HIV diagnosis and delayed ART start with negative implications for 
mother-to-child-transmission (MTCT) risk and maternal health.  
We aimed to assess whether migrant women with HIV encounter barriers in accessing HIV 
testing and care during pregnancy using contemporary data across several European 
countries. To do so, we compared three markers of suboptimal PMTCT interventions in 
migrant and native women: HIV diagnosis in late pregnancy in women undiagnosed at 
conception, late ART start in women diagnosed but untreated at conception and detectable 
viral load (VL) at delivery in women on antenatal ART. Late ART start in women diagnosed 
but not treated at conception may reflect challenges in retention in HIV care and suboptimal 
adherence,9-12 whilst a detectable VL at delivery is a surrogate indicator of MTCT risk and 
delayed ART start.13 
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We addressed these objectives using data from 2002 to 2012 in the European Pregnancy 
and Paediatric Cohort Collaboration (EPPICC) in EuroCoord, a large collaboration of HIV 
observational studies in pregnant women and children.14 
METHODS 
Study design and participants 
Four cohorts across ten European countries participating in EPPICC provided data on 
pregnancies of women diagnosed with HIV before or during pregnancy. The western arm 
(which included Belgium, Denmark, Germany, Italy, Netherlands, Poland and Sweden) of the 
European Collaborative Study (ECS), the UK and Ireland National Study of HIV in 
Pregnancy and Childhood (NSHPC), NENEXP (Spain) and the Madrid Cohort of HIV-
Infected Mother-Infant Pairs (Spain) submitted data on eligible pregnancies using a 
standardised format (modified HIV Collaboration Data Exchange Protocol, 
http://www.hicdep.org) to the coordinating centre. Each participating study centre was 
responsible for ensuring that ethics approval for the data merger and analysis was in place 
and for compliance with local and national data protection requirements. 
We included women who delivered a singleton live birth in the cohort countries between 
2002 and 2012; if a woman had repeated pregnancies during the study period, we included 
only the first one. We excluded women whose country of birth was unknown (445). We 
defined a migrant as a woman who delivered in a country different from her country of birth 
and a native (NAT) as a woman who delivered in her country of birth. We grouped countries 
of birth into seven world regions based on UN grouping categories:15 Western Europe and 
other Western countries, including North America, Australia and New Zealand (WEWC), 
Eastern Europe (EE), North Africa and The Middle East (NAME), Sub-Saharan Africa (SSA), 
Latin America (LA), The Caribbean (CRB), Asia and Oceania (excluding Australia and New 
Zealand) (ASIA/OC). 
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Statistical analysis 
We compared three markers of suboptimal PMTCT interventions in migrant and native 
women: (1) diagnosis in late pregnancy in women who were undiagnosed at conception; (2) 
late ART start in women who were diagnosed and untreated at conception; (3) detectable VL 
at delivery (up to 28 days before and seven days after delivery) in women who were on ART 
in pregnancy and delivered at ≥37 gestation weeks to exclude pregnancies with short ART 
duration because of pre-term delivery. 
We used 200 copies/mL as the cut-off for VL detectability due to changing use of assays 
with different detection limits over the study period. For similar reasons (i.e. changing 
guidelines over time and across European countries9), we defined a diagnosis in late 
pregnancy as a diagnosis at ≥20 gestation weeks and a late ART start as initiation after 28 
gestation weeks.  We defined the first CD4 count measured in pregnancy as the baseline 
CD4 count and assumed a baseline CD4 count<350 cells/µL at antenatal diagnosis to be an 
indicator of late presentation for HIV care and a CD4 count<200 cells/µL an indicator of 
advanced HIV disease.16 
We fitted logistic regression models to investigate whether maternal region of birth was a 
factor associated with the above-mentioned markers of suboptimal PMTCT intervention. We 
adjusted the analyses for other factors known to be associated with late antenatal care 
presentation:1 year of delivery (2002-2006 vs 2007-2012), maternal age (in tertiles <28, 28-
33, >33 years), parity at enrolment (no/yes), HIV transmission mode (injecting drug use, 
heterosexual, other/unknown) and country of delivery (Spain, UK/Ireland and other 
European countries). In addition, the analysis on VL at delivery included a priori the following 
factors associated with VL suppression:17-19 time of ART initiation in pregnancy, baseline 
CD4 count and combination ART (≥three ART drugs) versus a mono-dual ART (<3 ART 
drugs) regimen. Chi-square tests were performed to assess whether differences in 
proportions between native and migrant women were statistically significant (P<0.05). 
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Likelihood ratio test was used to determine if transmission category modified the association 
between diagnosis in late pregnancy and being a migrant woman. 
Statistical analyses were carried out using STATA v13.1 software (Stata Corp, College 
Station, Texas, USA).  
RESULTS  
Characteristics of participants 
There were 11795 women who delivered a singleton live birth between 2002 and 2012. Of 
these women, 1188 (10.1%) delivered in Spain, 9317 (79.0%) in UK/Ireland and 1290 
(10.9%) in other European countries; 9421 (79.9%) were migrants. The proportion of migrant 
women increased from 76.3% in 2002-2006 to 83.8% in 2007-2012.  The most prevalent 
region of birth was SSA (8151, 69.1%); other regions of birth represented less than 3% each 
of all women but these proportions varied across European countries. In Spain, 20.7% of 
women were from SSA, 9.8% from LA and 62.9% were native. Maternal characteristics by 
world region of birth are presented in Table 1.  
Most women (9817, 83.2%) had acquired HIV heterosexually; among native women and 
women from WEWC, injecting drug use (IDU) acquisition was relatively common (21.1% and 
16.8% respectively). Overall, 152 women (1.3% of the whole dataset) were reported as 
being vertically infected, mainly native women (85) and women from SSA (55). Gestational 
age at delivery was available for 11506 pregnancies, of which 14.8% (1704) were pre-term.  
Native women were more likely to deliver pre-term than migrant women (19.5% vs. 13.6%, 
P<0.001).   
Between 2002 and 2012, the MTCT rate declined from 1.78% (95%CI 1.07, 2.78) to 0.70% 
(95%CI 0.23, 1.63). There was no difference between the unadjusted MTCT rates in migrant 
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and native women (0.96% [95%CI 0.77, 1.17] versus 1.22% [0.82, 1.75] respectively, 
P=0.25). 
Markers of suboptimal PMTCT interventions 
Of the 11795 women, we identified 4797 women who were diagnosed in pregnancy; 31.9% 
(1529) of them were diagnosed at ≥20 gestational weeks, with this proportion varying by 
region of birth (Table 2). We further identified 2253 women who were diagnosed and 
untreated at conception and who started ART during their pregnancy; 13.1% (295) of them 
started ART at>28 gestational weeks. 
Migrant women were more likely to be HIV-diagnosed during pregnancy than native women 
(4134/9421 [43.9%] vs 663/2374 [27.9%], P<0.001) (maternal characteristics in SMTable1). 
At antenatal diagnosis migrant women were also more likely to have CD4<350 cells/µL 
(48.6% vs.29.5%, P<0.001) and more likely to have CD4<200 cells/µL (20.0% vs 9.3%, 
P<0.001). The proportions of women with low CD4 count at antenatal HIV diagnosis by 
region of birth are given in Figure 1. 
Native women were more likely to be diagnosed but untreated at conception than migrant 
women (602/2374 [25.4%] vs 1651/9421 [17.5%]; P<0.001) (maternal characteristics in 
SMTable2).  
 HIV diagnosis in late pregnancy in women undiagnosed at conception 
Migrant women were more likely to be diagnosed in late pregnancy than native women 
(1367/4134 [33.1%] vs. 162/663 [24.4%], P<0.001). The proportion of those diagnosed in 
late pregnancy was highest among women from NAME (15/33, 45.5%) and lowest among 
women from WEWC (21/111, 18.9%) (Table 2, SMTable 1). Analysis stratified by 
transmission mode (Pinteraction=0.0087) and adjusted for calendar year, age at delivery, 
country of delivery and parity indicated that women from EE, NAME and SSA were more 
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likely to be diagnosed in late pregnancy compared with native women (women who acquired 
HIV by heterosexual mode only - Table 3). The risk increased if a woman was parous, 
younger than 28 years, delivered before 2007 and in Spain. The small number of migrant 
women who acquired HIV by IDU and were diagnosed in late pregnancy (n=10) precluded 
further analysis. 
Late ART start in women diagnosed but untreated at conception  
ART was started in late pregnancy in 13.8% (83/602) of native and 12.8% (212/1651) of 
migrant women (SMTable2). In an analysis of 2193 women with full-term deliveries, adjusted 
for country of delivery, year of delivery, maternal age at delivery, mode of HIV transmission 
and parity, delivering before 2007 (OR 2.58, 95%CI 1.94, 3.42) and being parous (OR 1.45, 
95%CI 1.11, 1.90) were associated with late ART start but not being a migrant from SSA 
(OR 0.98, 95%CI 0.69, 1.37) or from other world regions (OR 0.90, 95%CI 0.54, 1.48) 
(SMTable3). In a sensitivity analysis including only women who acquired HIV heterosexually, 
being a migrant was not associated with late treatment initiation (OR [women from SSA vs. 
native women] 1.11, 95%CI 0.75, 1.64 ).  
Viral load at delivery 
Data on viral load at delivery were available for 5323 (56.6%) of women who met our 
inclusion criteria (full-term delivery and on antenatal ART, n=9406). Women who were 
native, delivered before 2007 and/or in Spain and/or started ART in early pregnancy were 
less likely to have data on viral load at delivery. Of these 5323 women, delivery VL was 
above 200 copies/mL in 807 (15.1%) women, comprising 674/4460 (15.1%) migrant and 
133/863 (15.4%) native (SMTable4). As expected, multivariable analysis suggested that late 
ART start in pregnancy was the strongest factor associated with having a detectable VL at 
delivery. Other factors associated with increased risk of non-suppressed VL included 
delivering between 2002-2006 rather than 2007-2012, having a baseline CD4 count<350 
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cells/µL and use of mono/dual ART rather than cART (SM Table 4) but not being a migrant. 
Sensitivity analyses restricted to women starting treatment in pregnancy (n=3705) confirmed 
the main analysis findings that being a migrant was not associated with a detectable VL at 
delivery (OR 1.06, 95%CI 0.79, 1.43) even after including only women who acquired HIV 
heterosexually (OR 1.20, 95%CI 0.86, 1.68). Among the sub-group of women starting ART 
late, 36% (271/754) of migrants delivered with a detectable VL versus 39% (42/109) of 
native women (P=0.60). 
 
DISCUSSION 
Our study has identified a large proportion of HIV-positive women in Europe delivering a live 
birth in 2002-2012 who were migrants, of whom 44% were diagnosed with HIV in their 
current pregnancy. At antenatal diagnosis 49% of migrant women had CD4<350 cells/µL 
compared to 29.5% of native women suggesting that pregnancy is an important opportunity 
for undiagnosed migrant women to learn their HIV status.20 Reassuringly, our analyses 
suggest that between 2002 and 2012 (our study period), PMTCT interventions have 
improved in both migrant and native women. Once on ART, migrant women had a good 
virological response and we did not observe any difference in the crude MTCT rate between 
migrant and native women. However, we found that migrant women, particularly those from 
SSA, NAME and EE were more likely to be diagnosed in late pregnancy but we did not 
identify delayed ART initiation among migrant women who were already diagnosed at 
conception but not on ART. 
The observed differences between migrant and native women with respect to late antenatal 
HIV diagnosis partly agree with previous studies conducted in France21 and Italy,22, 23 which 
reported that migrant women were more likely to receive late HIV screening and/or 
inappropriate antenatal care compared to native women, with higher rates of MTCT in 
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migrant women. Although we found that migrant women were less likely to know their HIV 
status at conception, more likely to be diagnosed late in pregnancy and more likely to be 
diagnosed with low CD4 counts, there was no difference in the proportion achieving 
undetectable VL by delivery between native and migrant women among those receiving 
antenatal ART and delivering at term. This suggests that duration of antenatal ART was 
sufficient to reduce MTCT risk in these migrant women, consistent with the earlier French 
study where there was no difference in rates of uncontrolled viremia at delivery between 
African- and French-born women in the ART era.21 Although outside the scope of this paper, 
it is also likely that among those mother-infant pairs with detectable maternal VL at delivery 
other PMTCT interventions were successfully applied, given the similar and low MTCT rates 
in migrant and native women. 
Antenatal HIV screening is the cornerstone of PMTCT, with timely identification of previously 
undiagnosed women allowing application of optimum interventions. We showed that, among 
women with unknown HIV status at conception, migrant women from EE, NAME and SSA 
were more likely to be diagnosed after 20 weeks gestation than native women after 
accounting for other factors associated with late antenatal care presentation.7 Although few 
Western European countries have routine repeat HIV testing for women with negative 
screens at antenatal booking, it is possible that some women in this “late screen” group 
acquired HIV in pregnancy and were diagnosed based on a second HIV test . Another 
finding was a higher rate of HIV diagnosis with severe immunosuppression among migrant 
women implying missing opportunities for earlier diagnosis and treatment. A recent Italian 
study has also reported similar findings, with women from SSA more likely to present with 
advanced HIV disease in pregnancy.24 Previous studies have identified barriers to accessing 
HIV testing and care experienced by migrants, such as time or financial constraints, 
language and cultural barriers and living and working conditions.4, 5, 25-27 
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In Europe, a large and increasing proportion of pregnant women with HIV are already aware 
of their HIV status at conception.1, 28, 29 Retention of patients in HIV care can be challenging, 
particularly postnatally, and a subsequent pregnancy often provides the means to re-
establish a woman in HIV care.17 We found that most diagnosed women not on treatment at 
conception started ART in the first or second trimester, and report no difference in risk of 
starting ART late between migrant and native women. Although we showed a nearly six-fold 
increased risk of delivery with detectable VL in women who were not on ART until the third 
trimester, this was driven by women delivering in the early years (2002-2007) reflecting 
changing guidelines. 
Another reassuring finding was a significant decline in risk of late ART start over calendar 
time. Western Europe has recorded low MTCT rates for many years, with continuing 
declines driven by high uptake of antenatal screening, a large and increasing proportion of 
women on suppressive ART at conception, and prompt start of ART in pregnancy for 
untreated women. However, socio-economic disparities in access to health care exist,30 and 
overall low MTCT rates do not preclude the existence of sub-groups at increased risk of poor 
outcomes, such as the one in six women here with non-suppressed VL at delivery or those 
who delivered pre-term. Given the benefits of early ART start for health and survival,31,32,34 
the considerable number of migrant women in Europe who access antenatal and HIV care 
services late is of public health concern.6  
Our study had some limitations. We excluded women whose country of birth was unknown. 
As there is no universally agreed definition of the term ‘migrant’ we used country of birth (as 
reported by the mother) to determine whether a woman was a migrant, but we did not 
attempt to distinguish between country of birth, nationality or ethnic group. We did not 
consider the legal status of a migrant, time of arrival in the country of delivery or language 
spoken, which may affect the ability to access the local health care system, as such 
information was unavailable. Data were driven by the NSHPC, the largest dataset, and by 
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women from SSA, who made up nearly 70% of the whole study population. We merged all 
women from SSA into one group, not acknowledging the rich cultural, ethnic and language 
diversity within SSA.7, 33 Although poor socioeconomic status may delay HIV diagnosis and 
start of ART30 and increase risk of virological non-suppression in treated adults,35 we were 
unable to adjust for socio-economic factors. As this study is of women diagnosed before or 
during delivery only, we could not explore migrant women’s risk of delivering with 
undiagnosed HIV infection (e.g. due to testing decline or incident infection in pregnancy). 
Women from countries with a high HIV prevalence may remain at elevated risk of HIV 
acquisition post migration36,37(e.g. 30% of SSA women living with HIV in France are 
estimated to have acquired HIV while in France37);  highlighting the importance of HIV 
testing current partners of pregnant women as well as HIV prevention measures for all 
women including those from high prevalence settings. 
In conclusion, we have shown that although some migrant women were more likely to be 
diagnosed in late pregnancy, there was no overall difference between migrant and native 
women with respect to achieving an undetectable VL by delivery. Good access to antenatal 
care will not only enable the implementation of PMTCT protocols but also optimise both 
maternal and child health outcomes generally. Similarly, tailored screening programmes for 
migrant communities, whether antenatal or for the general population, are needed to help 
improve the cascade of HIV care and broaden HIV prevention programmes. Wider access to 
HIV testing and care would give migrant women an opportunity to know their HIV-status 
before conceiving and either reinforce prevention measures or start ART before conception 
thus optimising PMTCT interventions and women’s health. Our findings indicate that 
particular attention should be given to facilitate access to services for migrant women with 
children.  
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Keypoints 
 In Europe a large proportion of pregnant women with HIV are migrants – mainly from 
sub-Saharan Africa, albeit with some differences between European countries.  
 Compared to pregnant native-born women, migrant women are less likely to know 
their HIV status at conception, more likely to be diagnosed in late pregnancy and at 
antenatal diagnosis, more likely to have low CD4 counts. 
 Although some migrant women are more likely to be diagnosed in late pregnancy, 
among those on ART there is no overall difference between migrant and native 
women with respect to achieving an undetectable viral load by delivery, a proxy 
indicator of MTCT risk. 
 Tailored screening programmes for migrant communities, whether antenatal or for 
the general population, are needed to help improve the cascade of HIV care and 
broaden HIV prevention programmes.  
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Table 1 Maternal characteristics of all women by world region of birtha 
 
NAT WEWC EE NAME SSA LA CRB ASIA/ 
OC 
Total 
 N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
 
2374 
(20.1) 
274 
(2.3) 
188 
(1.6) 
79 
(0.7) 
8151 
(69.1) 
198 
(1.7) 
252 
(2.1) 
279 
(2.7) 
11795 
(100.0) 
Country of delivery         
  Spain 
747 
(31.5) 
5 
(1.8) 
27 
(14.4) 
21 
(26.6) 
246 
(3.0) 
116 
(58.6) 
22 
(8.7) 
4 
(1.4) 
1188 
(10.1) 
  UK/   
  Ireland 
1235 
(52.0) 
248 
(90.5) 
109 
(58.0) 
31 
(39.2) 
7194 
(88.3 
39 
(19.7) 
226 
(89.7) 
235 
(84.2) 
9317 
(79.0) 
  Other b 
392 
(16.5) 
21 
(7.7) 
52 
(27.7) 
27 
(34.2) 
711 
(8.7) 
43 
(21.7) 
4 
(1.6) 
40 
(14.3) 
1290 
(10.9) 
Year of delivery         
  2002- 
  2006 
1466 
(61.8) 
116 
(42.3) 
70 
(37.2) 
49 
(62.0) 
4091 
(50.2) 
110 
(55.6) 
134 
(53.2) 
141 
(50.5) 
6177 
(52.4) 
  2007- 
  2012 
908 
(38.3) 
158 
(57.7) 
118 
(62.8) 
30 
(38.0) 
4060 
(49.8) 
88 
(44.4) 
118 
(46.8) 
138 
(49.5) 
5618 
(47.6) 
Parity (n=11652)         
  Yes 
1205 
(52.2) 
114 
(41.8) 
59 
(33.0) 
40 
(52.6) 
4430 
(54.7) 
110 
(59.8) 
158 
(63.5) 
131 
(47.5) 
6247 
(53.6) 
Number of ART drugs in pregnancy       
  <3 ART  
280 
(11.8) 
23 
(8.4) 
19 
(10.1) 
6 
(7.6) 
594 
(7.3) 
16 
(8.1) 
23 
(9.1) 
16 
(5.7) 
977 
(8.3) 
  ≥3ART 
1939 
(81.7) 
242 
(88.3) 
154 
(81.9) 
67 
(84.8) 
7224 
(88.6) 
167 
(84.3) 
220 
(87.3) 
251 
(90.0) 
10264 
(87.0) 
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  Unknown 
155 
(6.5) 
9 
(3.3) 
15 
(8.0) 
6 
(7.6) 
333 
(4.1) 
15 
(7.6) 
9 
(3.6) 
12 
(4.3) 
554 
(4.7) 
ART at conception (n=11245)       
  No 
1469 
(68.1 
193 
(72.3) 
136 
(75.6) 
56 
(73.7) 
5616 
(71.3) 
123 
(69.1) 
197 
(80.1) 
193 
(71.8) 
7983 
(71.0) 
  Yes 
688 
(31.9) 
74 
(27.7) 
44 
(24.4) 
20 
(26.3) 
2256 
(28.7) 
55 
(30.9) 
49 
(19.9) 
76 
(28.3) 
3262 
(29.0) 
CD4 (cells/µL) at baseline (n=10121)       
  <350 
552 
(31.7) 
65 
(26.2) 
60 
(37.3) 
23 
(34.9) 
3324 
(45.6) 
51 
(39.5) 
67 
(28.3) 
113 
(44.8) 
4255 
(42.0) 
  <200 
165 
(9.5) 
21 
(8.5) 
13 
(8.1) 
10 
(15.2) 
1179 
(16.2) 
14 
(10.9) 
17 
(7.2) 
39 
(15.5) 
1458 
(14.4) 
a NAT=native population, WEWC=Western Europe and similar countries, EE= Eastern Europe, 
NAME=North Africa and the Middle East, SSA-Sub-Saharan Africa, LA=Latin America, CRB=Caribbean, 
ASIA/OC=Asia and Oceania; b Belgium, Denmark, Germany, Italy, Netherlands, Poland, Sweden; c 
Women with no antenatal ART data excluded; d Pre-term (<37 GW) deliveries and women with 
missing information on antenatal ART excluded. 
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Table 2 Markers of suboptimal PMTCT interventions in women with HIV by world 
region of birth 
 NAT WEWC EE NAME SSA LA CRB ASIA/ OC  Total 
Women diagnosed in current pregnancy (n=4797) 
 n=663 n=111 n=89 n=33 n=3557 n=74 n=123 n=147 n=4797 
Diagnosed 
  at≥20GW 
162 
(24.4%) 
 
21 
(18.9%) 
31 
(34.8%) 
15 
(45.5%) 
1206 
(33.9%) 
24 
(32.4%) 
32 
(26.0%) 
38 
(25.9%) 
1529 
(31.9%) 
Women  diagnosed but untreated at conception (n=2253) 
 n=602 n=60 n=35 n=16 n=1423 n=41 n=50 n=26 n=2253 
ART start 
  >28GW 
83 
(13.8%) 
 
6 
(10.0%) 
2 
(5.7%) 
2 
(12.5%) 
183 
(12.9%) 
7 
(17.1%) 
8 
(16.0%) 
4 
(15.4%) 
295 
(13.1%) 
Women on antenatal ART with viral load at delivery (n=5323)a  
 n=863 n=143 n=84 n=34 n=3858 n=81 n=130 n=130 n=5323 
>200 
copies/mL 
133 
(15.4% ) 
 
23 
 (16.1%) 
13 
 (15.5% ) 
6  
(17.7%) 
579 
(15.0%) 
17 
(21.0%) 
17 
(13.1%) 
19 
(14.6%) 
807 
(15.1%) 
NAT=native, WEWC=Western Europe and similar countries, EE= Eastern Europe, NAME=North Africa 
and the Middle East, SSA=Sub-Saharan Africa, LA=Latin America, CRB=Caribbean, ASIA/OC=Asia and 
Oceania; GW=gestational weeks;  
a pre-term (<37GW) deliveries excluded.   
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Table 3 Factors associated with being diagnosed at ≥20 gestational weeks rather than 
earlier in women diagnosed in pregnancy 
 Antenatal 
HIV 
diagnosis 
at <20GW 
Antenatal 
HIV 
diagnosis at  
≥20GW 
Crude OR 
(95% CI) 
Adjusteda OR  
(95% CI) 
(Heterosexual 
only n= 4241) 
Adjusteda OR 
(95% CI) 
(IDU only n= 81) 
 N (%) N (%)    
 3268(68.1) 1529(31.9%)    
World region of birth    
  NAT   501(75.6) 162(24.3) 1.00 1.00 1.00 
  WEW   90(81.1) 21(18.9) 0.72(0.43,1.20) 1.22(0.69,2.16) 0.31 (0.05, 2.00) 
  EE   58(65.2) 31(34.8) 1.65(1.03,2.65) 2.00(1.11,3.62) 1.39 (0.23, 8.52) 
  NAME   18(54.6) 15(45.5) 2.58(1.27,5.23) 3.16(1.43,6.99) - 
  SSA   2351(66.1) 1206(33.9) 1.59(1.31,1.92) 2.12(1.67,2.69) 0.49 (0.10, 2.45) 
  LA   50(67.6) 24(32.4) 1.48(0.88,2.49) 1.56(0.86,2.84) - 
  CRB   91(74.0) 32(26.0) 1.09(0.70,1.69) 1.21(0.75,1.95) - 
  ASIA/OC   109(74.2) 38(25.9) 1.08(0.72,1.62) 1.45(0.90,2.33) - 
Country of delivery     
  UK/Ireland 2861(68.9) 1294(31.4) 1.00 1.00 1.00 
  Spain 143(57.4) 106(42.6) 1.64(1.26,2.12) 1.76(1.24,2.51) 1.50 (0.33, 6.81) 
  Other EU  264(67.2) 129(32.8) 1.08(0.87,2.12) 0.89(0.67,1.20) 1.13 ( 0.20, 6.41) 
Year of delivery     
  2002-2006 1722(62.5) 1033(37.5) 1.00 1.00 1.00 
  2007-2012 1546(75.7) 496(24.3) 0.53(0.47,0.61) 0.88(0.85,0.90) 0.90 (0.72, 1.12) 
Maternal age at delivery (years)    
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  <28 1252(65.3) 665(34.7) 1.28(1.10,1.49) 1.38(1.18,1.62) 1.02 (0.35, 2.96) 
  28-32 1131(69.9) 486(30.1) 1.03(0.88,1.49) 1.00 1.00 
  >32 867(70.7) 360(29.3) 1.00 1.01(0.85,1.21) 1.63 (0.42, 6.38) 
Parity      
  Nulliparous 1810(70.7) 750(29.3) 1.00 1.00 1.00 
  Parous 1442(65.2) 770(34.8) 1.29(1.14,1.46) 1.37(1.19,1.58) 2.27 (0.77, 6.71) 
 
GW=gestational weeks; IDU= NAT=native population; WEWC=Western Europe and similar countries; 
EE= Eastern Europe; NAME=North Africa and the Middle East; SSA-Sub-Saharan Africa; LA=Latin 
America; CAR=Caribbean; ASIA/OC=Asia and Oceania; a Odds ratios adjusted for world region of 
birth, country of delivery, year of delivery, maternal age at delivery and parity and stratified by 
heterosexual mode and IDU (intravenous drug use) mode  of HIV acquisition (Pinteraction= 0.0087). 
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